Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OM-85

Phase 3Small molecule

1

Indications

3

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionsActive, not recruiting

Respiratory Tract InfectionsPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Wheezing

NCT05857930

Clinical

Trials by Indication[1]

Respiratory tract infection1 trial

Effect of OM-85 on Respiratory Tract Infections and Adenoid Tissue in Children With Adenoid Hypertrophy

Unknown status·—·Phase 4·NCT03243565·68 enrolled

Wheezing1 trial

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo Given in Children Aged 6 Months to 5 Years With Recurrent Wheezing

Active, not recruiting·OOM Pharma SA·Phase 2·NCT05857930·296 enrolled

Respiratory Tract Infections1 trial

A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years With Wheezing Lower Respiratory Illness

Active, not recruiting·OOM Pharma SA·Approved·NCT05677763·525 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for OM-85. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OM-85 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OM-85. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OM Pharma SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOM Pharma SA

Related News